Teva invests further in diabetes treatment firm Andromeda
Israeli generic drugs giant Teva Pharmaceutical Industries Ltd. has exercised its option to invest an additional $11.9 million in diabetes drug developer Andromeda Biotech at a company value of $170 million, report the local news service Globes Online.
As part of the exercise of the option, Andromeda's parent company, Clal Biotechnology Industries will also invest $5.6 million, bringing the total investment in the company to $17.5 million. The investment will reduce Clal Biotech's stake in Andromeda from 89% to 84% (77% on a fully diluted basis.
Andromeda will use the proceeds to finance the continuation of the Phase III clinical trial of its leading drug candidate, DiaPep277, for the treatment of type 1 diabetes, according to the Globes report. The trial includes 450 recently diagnosed patients aged 20-45 at 100 medical centers worldwide.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze